| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President and CEO | Director | Chief Executive Officer
2 companies
Richard J Daly is President and CEO at CPRX, with reported holdings spanning 2 companies. Richard J Daly's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $29K at current prices.
Our model assigns Richard J Daly a below-average insider score of 23/100, based on 3 past trades. Over a 12-month horizon, the one trade was not profitable, with an average 12-month return of -57.7%.
Richard J Daly's largest disclosed position is in PALI as Chief Executive Officer, worth about $29K. Net of sales, the PALI filings show accumulation of 147,871 shares.
Richard J Daly has 26 Form 4 filings on record from September 2016 to January 2026, across 2 companies: President and CEO at Catalyst Pharmaceuticals (CPRX), 2022–2026; Chief Executive Officer at Palisade Bio (PALI), 2016–2017.
The 41 reported transactions were 14 option exercises, 10 option or other derivative awards, 7 tax withholdings and 7 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 7 purchases worth about $90K and 3 sales worth about $2.5M.
The largest open-market purchase was 7,500 shares of PALI at an average $4.00 on May 17, 2017, about $30K.
The largest open-market sale was 70,000 shares of CPRX at an average $24.86 on May 30, 2025, about $1.7M.
None of the 3 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 26, 2025 | CPRX Catalyst Pharmaceuticals, Inc. | President and CEO | Sale+OE | 22,970 | $20.62 | $473,641.40 | -9.2% | +17.9% | - | |
| May 30, 2025 | CPRX Catalyst Pharmaceuticals, Inc. | President and CEO | Sell | 70,000 | $24.86 | $1,740,200.00 | -25.9% | -18.3% | - | |
| Jun 4, 2024 | CPRX Catalyst Pharmaceuticals, Inc. | President and CEO | Sale+OE | 17,323 | $15.98 | $276,734.93 | -6.9% | +23.1% | +57.7% | |
| May 17, 2017 | PALI Palisade Bio, Inc. | Chief Executive Officer | Buy | 7,500 | $4.00 | $30,000.00 | +47.4% | - | - | |
| Feb 24, 2017 | PALI Palisade Bio, Inc. | Chief Executive Officer | Buy | 2,591 | $3.86 | $10,001.26 | +19.6% | - | - | |
| Jan 25, 2017 | PALI Palisade Bio, Inc. | Chief Executive Officer | Buy | 2,841 | $3.52 | $10,000.32 | +27.4% | - | - | |
| Dec 23, 2016 | PALI Palisade Bio, Inc. | Chief Executive Officer | Buy | 32,259 | $0.31 | $10,000.29 | +31.4% | - | - | |
| Nov 25, 2016 | PALI Palisade Bio, Inc. | Chief Executive Officer | Buy | 35,715 | $0.28 | $10,000.20 | +53.3% | - | - | |
| Oct 25, 2016 | PALI Palisade Bio, Inc. | Chief Executive Officer | Buy | 35,715 | $0.28 | $10,000.20 | +114.3% | - | - | |
| Sep 23, 2016 | PALI Palisade Bio, Inc. | Chief Executive Officer | Buy | 31,250 | $0.32 | $10,000.00 | New | - | - |